Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
US-11891453-B2 · Feb 6, 2024 · US
Anti-variant Fc-region antibodies and method of use
US11970550B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11970550-B2 |
| Application number | US-202017113684-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 7, 2020 |
| Priority date | Oct 29, 2015 |
| Publication date | Apr 30, 2024 |
| Grant date | Apr 30, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations 1253A/H310A/H435A in the Fc-region, and methods of using the same.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated antibody comprising (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 10; (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 13; (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 17; (d) a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 24; (e) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 26; and (f) a HVR-L3 comprising the amino acid sequence of SEQ ID NO: 29. 2. The antibody according to claim 1 , wherein the antibody is a monoclonal antibody. 3. The antibody according to claim 1 , wherein the antibody is a humanized, or chimeric antibody. 4. The antibody according to claim 1 , wherein the antibody is an antibody fragment. 5. A conjugate comprising the antibody according to claim 1 , and a detectable label. 6. A method of detecting in a biological fluid sample the presence of a therapeutic antibody of a IgG1 or IgG4 subclass comprising the variant Fc-region with the mutation P329G, L234A, and L235A or the mutations P329G, L234A, L235A, I253A, H310A and H435A, wherein the amino-acid positions are numbered according to Kabat EU index, the method comprising (a) contacting the biological fluid sample with the antibody of claim 1 , wherein the antibody of claim 1 specifically binds the therapeutic antibody of the IgG1 or IgG4 subclass comprising the variant Fc-region with the mutation P329G, L234A, and L235A or the mutations P329G, L234A, L235A, I253A, H310A and H435A, to form a complex; and (b) detecting the complex, wherein detection of the complex correlates to the presence of the therapeutic antibody of the IgG1 or IgG4 subclass comprising the variant Fc-region with the mutation P329G, L234A, and L235A or the mutations P329G, L234A, L235A, I253A, H310A and H435A, wherein the antibody of claim 1 is either a capture or tracer antibody.
Assignees
Inventors
Classifications
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)} · CPC title
CH2 domain · CPC title
CH3 domain · CPC title
- C07K16/42Primary
against immunoglobulins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11970550B2 cover?
- The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations 1253A/H310A/H435A in the Fc-region, and methods of using the same.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification C07K16/42. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).